Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-8245 SCHEMBL29385507 | 1.00 | SCD (1.00) | SCDSCD5 | |
| Mk-8245 SCHEMBL31482518 | 0.96 | SCD (0.92) | SCDSCD5 | |
| SCHEMBL18058595 | 0.93 | SCD (0.86) | SCDSCD5 | |
| SCHEMBL3320435 | 0.85 | SCD (0.74) | SCDSCD5 | |
| SCHEMBL13261130 | 0.85 | SCD (0.74) | SCDSCD5 | |
| SCHEMBL4543845 | 0.85 | SCD (0.74) | SCDSCD5 | |
| SCHEMBL473052 | 0.85 | SCD (0.73) | SCDSCD5 | |
| SCHEMBL473015 | 0.84 | SCD (0.73) | SCDSCD5 | |
| SCHEMBL31414369 | 0.84 | SCD (0.73) | SCDSCD5 | |
| SCHEMBL10129469 | 0.84 | SCD (0.73) | SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | LIFECEUTIX CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4431102-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | Lifeceutix Co., Ltd. (KR) | 2024-09-18 | — | — | EP | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240060072-A1 | METHOD AND COMPOSITION FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, ASSOCIATED CONDITIONS AND SYMPTOMS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-02-22 | — | — | US | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2011019538-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010056708-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| EP-2099793-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064474-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008064474-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | SCD 1066/4885SCD5 936/4885 |
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885SCD5 1591/4885 |
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885SCD5 1591/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD 1194/4885SCD5 1591/4885 |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | GLA, LIMS1, TP53 | SCD 881/4885SCD5 187/4885 |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | SCD 1/4885SCD5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.